Clinical application of brain perfusion SPECT/CT imaging with NeuroGamTM software in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease

被引：0
作者：
Lei Z. [1 ,2 ]
Wu H. [1 ,2 ]
Ou Y. [1 ]
Xu Q. [1 ]
Shi X. [1 ]
Shi K. [1 ]
Zhao Q. [1 ]
Ding J. [3 ]
Yin Y. [4 ]
Wang X. [5 ]
Liu X. [6 ]
Lou J. [2 ]
Liu X. [6 ]
机构：
[1] Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai
[2] Department of Nuclear Medicine, Fudan University Pudong Medical Center, Shanghai
[3] Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai
[4] Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai
[5] Department of Neurology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai
[6] Department of Neurology, The Tenth People's Hospital Affiliated to Tongji University, Shanghai
来源：
He Jishu/Nuclear Techniques | 2022年 / 45卷 / 02期
关键词：
Alzheimer's disease; Cerebral blood flow perfusion; Mild cognitive impairment; Single photon emission computer tomography; Subjective cognitive decline;
D O I：
10.11889/j.0253-3219.2022.hjs.45.020301
中图分类号：
学科分类号：
摘要：
Background: Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are a transitional state between normal aging and mild dementia, and most of them have potential Alzheimer's Disease (AD) pathology. Studying the pathophysiological characteristics of SCD and MCI is helpful to the early diagnosis of AD. Purpose: This study aims to investigate the brain perfusion differences among SCD, MCI and AD, and to evaluate the application value of brain perfusion SPECT/CT imaging combined with NeuroGamTM software in these diseases. Methods: From July 2020 to April 2021, 15 patients with SCD, 29 patients with MCI and 36 patients with AD were collected from several general hospitals in Shanghai. All subjects underwent neuropsychological test and 99mTc-ECD brain perfusion SPECT/CT imaging. The perfusion levels of Brodmann areas (BA) in the three groups were semi-quantitatively analyzed by NeuroGamTM, and compared with normal database. Student's t-test, one-way analysis of variance and rank sum test were used for the comparison of quantitative variables. Pearson's chi-squared test was used for the comparison of qualitative variables. Results: There is no significant difference in BA 4~11, 17~25, 28, 31~32, 36~40 and 44~47 between SCD group and MCI group. The mean perfusion values of BA 8-right(R), 20-left(L), 21R, 23L, 23R, 24L, 31L, 38L, 38R and 45R in SCD group are significantly higher than those in AD group (p<0.016 7). The mean perfusion values of BA 21R, 23R, 23R, 31L and 39L of MCI group are significantly higher than those in AD group (p<0.016 7). Compared with the normal database, SCD group show hypoperfusion in BA 24L, 24R, 28L and 28R whilst MCI group show hypoperfusion in BA 21L, 21R, 23R, 24L, 24R, 25L, 25R, 28L, 28R, 36L, 36R, 38R and 47L, and AD group show hypoperfusion in BA 21L, 21R, 22L, 23L, 23R, 24L, 24R, 25R, 28L, 28R, 32L, 32R, 36L, 36R, 47L. Conclusions: There are differences in the degree and range of hypoperfusion in SCD, MCI and AD. Brain perfusion SPECT/CT imaging combined with NeuroGamTM software has certain application value in these diseases and can be used as an auxiliary diagnostic tool. © 2022, Science Press. All right reserved.
引用
收藏
相关论文
共 29 条
  • [1] Sperling R A, Aisen P S, Beckett L A, Et al., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, 7, 3, pp. 280-292, (2011)
  • [2] Henderson T A., The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging, CNS Spectrums, 17, 4, pp. 176-206, (2012)
  • [3] FU Peng, WEI Lingge, Clinical application of NeuroGam software in analysis of functional brain imaging in nuclear medicine, Chinese Journal of Nuclear Medicine and Molecular Imaging, 39, 3, pp. 178-181, (2019)
  • [4] Albert M S, Dekosky S T, Dickson D, Et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, 7, 3, pp. 270-279, (2011)
  • [5] Mckhann G M, Knopman D S, Chertkow H, Et al., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, 7, 3, pp. 263-269, (2011)
  • [6] LOU Jingjing, LIU Zhuang, ZHOU Yujing, Et al., Evaluation of surgical efficacy using <sup>99m</sup>Te-chnetium ethyl cystine dimer brain perfusion single photon emission computer tomography/computer tomography combined with NeuroGam software in moyamoya disease, Shanghai Medical Journal, 42, 8, pp. 483-486, (2019)
  • [7] Lei Z, Lou J J, Wu H, Et al., Regional cerebral perfusion in patients with amnestic mild cognitive impairment: effect of cerebral small vessel disease, Annals of Nuclear Medicine, 36, 1, pp. 43-51, (2022)
  • [8] Valotassiou V, Papatriantafyllou J, Sifakis N, Et al., Clinical evaluation of brain perfusion SPECT with brodmann areas mapping in early diagnosis of Alzheimer's disease, Journal of Alzheimer's Disease: JAD, 47, 3, pp. 773-785, (2015)
  • [9] Pennanen C, Kivipelto M, Tuomainen S, Et al., Hippocampus and entorhinal cortex in mild cognitive impairment and early AD, Neurobiology of Aging, 25, 3, pp. 303-310, (2004)
  • [10] Braak H, Braak E., Neuropathological stageing of alzheimer-related changes, Acta Neuropathologica, 82, 4, pp. 239-259, (1991)
123